445 related articles for article (PubMed ID: 26921204)
1. Effect of Telbivudine Versus Other Nucleos(t)ide Analogs on HBeAg Seroconversion and Other Outcomes in Patients with Chronic Hepatitis B: A Network Meta-Analysis.
Liang X; Fan R; Sun J; Shaikh J; Taneja A; Gupta S; Hamed K
Adv Ther; 2016 Apr; 33(4):519-31. PubMed ID: 26921204
[TBL] [Abstract][Full Text] [Related]
2. HBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Nucleos(t)ide Analog Treatment: A Systematic Review and Network Meta-Analysis.
Xing T; Xu H; Cao L; Ye M
PLoS One; 2017; 12(1):e0169444. PubMed ID: 28107377
[TBL] [Abstract][Full Text] [Related]
3. Telbivudine versus entecavir for nucleos(t)ide-naive HBeAg-positive chronic hepatitis B: a meta-analysis.
Liu H; Wang X; Wan G; Yang Z; Zeng H
Am J Med Sci; 2014 Feb; 347(2):131-8. PubMed ID: 23563307
[TBL] [Abstract][Full Text] [Related]
4. Nucleos(t)ide analogues for the treatment of chronic hepatitis B: a systematic review with network meta-analysis.
Geng J; Bao H; Chen Y; Shi L; Geng J; Wang Q; Yu H
Expert Rev Anti Infect Ther; 2020 Aug; 18(8):823-834. PubMed ID: 32329638
[TBL] [Abstract][Full Text] [Related]
5. Renal Function in Nucleos(t)ide Analog-Treated Patients With Chronic Hepatitis B: A Systematic Literature Review and Network Meta-Analysis.
Chan HL; Shaikh J; Gupta S; Hamed K
Adv Ther; 2016 May; 33(5):862-75. PubMed ID: 27146675
[TBL] [Abstract][Full Text] [Related]
6. Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B.
Dakin H; Fidler C; Harper C
Value Health; 2010 Dec; 13(8):934-45. PubMed ID: 20825624
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the 48-week efficacy between entecavir and adefovir in HBeAg-positive nucleos(t)ide-naïve Asian patients with chronic hepatitis B: a meta-analysis.
Zhao P; Liu W; Zhao J; Guan Q
Virol J; 2011 Feb; 8():75. PubMed ID: 21342505
[TBL] [Abstract][Full Text] [Related]
8. Cross-study analysis of the relative efficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside-naive patients.
Dienstag JL; Wei LJ; Xu D; Kreter B
Clin Drug Investig; 2007; 27(1):35-49. PubMed ID: 17177578
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the forty-eight week efficacy between telbivudine and entecavir in HBeAg-positive Asian patients with chronic hepatitis B: A meta-analysis.
Wang N; Hu HD; Sun H; Feng Q; Hu P; Liu Q; Ren H
Turk J Gastroenterol; 2013; 24(3):230-40. PubMed ID: 24226716
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
Luo XD; Chen XF; Zhou Y; Chen XP
J Viral Hepat; 2017 Nov; 24 Suppl 1():36-42. PubMed ID: 29082651
[TBL] [Abstract][Full Text] [Related]
11. Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion.
Lau GK
Liver Int; 2010 Apr; 30(4):512-20. PubMed ID: 20102511
[TBL] [Abstract][Full Text] [Related]
12. Off-treatment efficacy of 3-year nucleos(t)ide analogues in chronic hepatitis B patients.
Lin CC; Bair MJ; Chen CJ; Lee KH; Chen MJ; Liu CY; Chang CW; Hu KC; Liou TC; Lin SC; Wang HY; Chu CH; Shih SC; Wang TE
Kaohsiung J Med Sci; 2016 Jan; 32(1):10-5. PubMed ID: 26853169
[TBL] [Abstract][Full Text] [Related]
13. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses.
Woo G; Tomlinson G; Nishikawa Y; Kowgier M; Sherman M; Wong DK; Pham B; Ungar WJ; Einarson TR; Heathcote EJ; Krahn M
Gastroenterology; 2010 Oct; 139(4):1218-29. PubMed ID: 20600036
[TBL] [Abstract][Full Text] [Related]
14. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP
Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
[TBL] [Abstract][Full Text] [Related]
15. Treatment of chronic hepatitis B: case selection and duration of therapy.
Leung N
J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
[TBL] [Abstract][Full Text] [Related]
16. Entecavir for the treatment of chronic hepatitis B infection.
Shepherd J; Gospodarevskaya E; Frampton G; Cooper K
Health Technol Assess; 2009 Oct; 13 Suppl 3():31-6. PubMed ID: 19846026
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Telbivudine Compared to Entecavir Among HBeAg+ Chronic Hepatitis B Patients: a Meta-Analysis Study.
Liang J; Jiang MJ; Deng X; Xiao Zhou X
Hepat Mon; 2013; 13(6):e7862. PubMed ID: 24032045
[TBL] [Abstract][Full Text] [Related]
18. Effects of telbivudine and entecavir for HBeAg-positive chronic hepatitis B: a meta-analysis.
Su QM; Ye XG
World J Gastroenterol; 2012 Nov; 18(43):6290-301. PubMed ID: 23180951
[TBL] [Abstract][Full Text] [Related]
19. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
[TBL] [Abstract][Full Text] [Related]
20. Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials.
Wong WWL; Pechivanoglou P; Wong J; Bielecki JM; Haines A; Erman A; Saeed Y; Phoon A; Tadrous M; Younis M; Rayad NZ; Rac V; Janssen HLA; Krahn MD
Syst Rev; 2019 Aug; 8(1):207. PubMed ID: 31426837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
